These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 21148494)

  • 1. Age-specific effectiveness of an oil-in-water adjuvanted pandemic (H1N1) 2009 vaccine against confirmed infection in high risk groups in England.
    Andrews N; Waight P; Yung CF; Miller E
    J Infect Dis; 2011 Jan; 203(1):32-9. PubMed ID: 21148494
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Usefulness of health registries when estimating vaccine effectiveness during the influenza A(H1N1)pdm09 pandemic in Norway.
    Guzmán Herrador BR; Aavitsland P; Feiring B; Riise Bergsaker MA; Borgen K
    BMC Infect Dis; 2012 Mar; 12():63. PubMed ID: 22429643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized, multicenter trial of a single dose of AS03-adjuvanted or unadjuvanted H1N1 2009 pandemic influenza vaccine in children 6 months to <9 years of age: safety and immunogenicity.
    Langley JM; Reich D; Aggarwal N; Connor D; Lebel MH; Gupta A; Garfield H; Li P; Madan A; Vaughn DW
    Pediatr Infect Dis J; 2012 Aug; 31(8):848-58. PubMed ID: 22801094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-Term Persistence of Cell-Mediated and Humoral Responses to A(H1N1)pdm09 Influenza Virus Vaccines and the Role of the AS03 Adjuvant System in Adults during Two Randomized Controlled Trials.
    van der Most RG; Clément F; Willekens J; Dewé W; Walravens K; Vaughn DW; Leroux-Roels G
    Clin Vaccine Immunol; 2017 Jun; 24(6):. PubMed ID: 28446441
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and persistence of the humoral and cellular immune responses induced by 2 doses of an AS03-adjuvanted A(H1N1)pdm09 pandemic influenza vaccine administered to infants, children and adolescents: Two open, uncontrolled studies.
    Garcia-Sicilia J; Arístegui J; Omeñaca F; Carmona A; Tejedor JC; Merino JM; García-Corbeira P; Walravens K; Bambure V; Moris P; Caplanusi A; Gillard P; Dieussaert I
    Hum Vaccin Immunother; 2015; 11(10):2359-69. PubMed ID: 26176592
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictors of immune response and reactogenicity to AS03B-adjuvanted split virion and non-adjuvanted whole virion H1N1 (2009) pandemic influenza vaccines.
    Andrews NJ; Walker WT; Finn A; Heath PT; Collinson AC; Pollard AJ; Snape MD; Faust SN; Waight PA; Hoschler K; Sheasby L; Waddington C; Kerridge S; Chalk J; Reiner A; John T; Fletcher M; Allen R; Fineman N; Wilkins S; Casey M; Michaelis L; Oeser C; Okike I; Ladhani S; Miller E
    Vaccine; 2011 Oct; 29(45):7913-9. PubMed ID: 21875635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Narcolepsy, 2009 A(H1N1) pandemic influenza, and pandemic influenza vaccinations: what is known and unknown about the neurological disorder, the role for autoimmunity, and vaccine adjuvants.
    Ahmed SS; Schur PH; MacDonald NE; Steinman L
    J Autoimmun; 2014 May; 50():1-11. PubMed ID: 24559657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term persistence of humoral and cellular immune responses induced by an AS03A-adjuvanted H1N1 2009 influenza vaccine: an open-label, randomized study in adults aged 18-60 years and older.
    Van Damme P; Kafeja F; Bambure V; Hanon E; Moris P; Roman F; Gillard P
    Hum Vaccin Immunother; 2013 Jul; 9(7):1512-22. PubMed ID: 23571166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Open-label, randomised, parallel-group, multicentre study to evaluate the safety, tolerability and immunogenicity of an AS03(B)/oil-in-water emulsion-adjuvanted (AS03(B)) split-virion versus non-adjuvanted whole-virion H1N1 influenza vaccine in UK children 6 months to 12 years of age.
    Waddington C; Andrews N; Hoschler K; Walker W; Oeser C; Reiner A; John T; Wilkins S; Casey M; Eccleston P; Allen R; Okike I; Ladhani S; Sheasby E; Waight P; Collinson A; Heath P; Finn A; Faust S; Snape M; Miller E; Pollard A
    Health Technol Assess; 2010 Oct; 14(46):1-130. PubMed ID: 20923610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial.
    McElhaney JE; Beran J; Devaster JM; Esen M; Launay O; Leroux-Roels G; Ruiz-Palacios GM; van Essen GA; Caplanusi A; Claeys C; Durand C; Duval X; El Idrissi M; Falsey AR; Feldman G; Frey SE; Galtier F; Hwang SJ; Innis BL; Kovac M; Kremsner P; McNeil S; Nowakowski A; Richardus JH; Trofa A; Oostvogels L;
    Lancet Infect Dis; 2013 Jun; 13(6):485-96. PubMed ID: 23518156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Administration of AS03B-adjuvanted A(H1N1)pdm09 vaccine in children aged <3 years enhances antibody response to H3 and B viruses following a single dose of trivalent vaccine one year later.
    Hoschler K; Andrews NJ; Faust SN; Finn A; Pollard AJ; Snape MD; Walker WT; Zambon M; Miller E
    Clin Infect Dis; 2014 Jan; 58(2):181-7. PubMed ID: 24149079
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized, controlled non-inferiority trial comparing A(H1N1)pmd09 vaccine antigen, with and without AS03 adjuvant system, co-administered or sequentially administered with an inactivated trivalent seasonal influenza vaccine.
    Langley JM; Frenette L; Chu L; McNeil S; Halperin S; Li P; Vaughn D
    BMC Infect Dis; 2012 Oct; 12():279. PubMed ID: 23110320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and safety of AS03-adjuvanted 2009 influenza A H1N1 vaccine in children 6-35 months.
    Carmona A; Omeñaca F; Tejedor JC; Merino JM; Vaman T; Dieussaert I; Gillard P; Arístegui J
    Vaccine; 2010 Aug; 28(36):5837-44. PubMed ID: 20600478
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An observer-blind, randomized, multi-center trial assessing long-term safety and immunogenicity of AS03-adjuvanted or unadjuvanted H1N1/2009 influenza vaccines in children 10-17 years of age.
    Poder A; Simurka P; Li P; Roy-Ghanta S; Vaughn D
    Vaccine; 2014 Feb; 32(9):1121-9. PubMed ID: 24252703
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An indirect comparison meta-analysis of AS03 and MF59 adjuvants in pandemic influenza A(H1N1)pdm09 vaccines.
    Hauser MI; Muscatello DJ; Soh ACY; Dwyer DE; Turner RM
    Vaccine; 2019 Jul; 37(31):4246-4255. PubMed ID: 31253447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and immunogenicity of an MF59-adjuvanted A/H1N1 pandemic influenza vaccine in children from three to seventeen years of age.
    Knuf M; Leroux-Roels G; Rümke HC; Abarca K; Rivera L; Lattanzi M; Pedotti P; Arora A; Kieninger-Baum D; Della Cioppa G
    Vaccine; 2015 Jan; 33(1):174-81. PubMed ID: 25444803
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monovalent inactivated split-virion AS03-adjuvanted pandemic influenza A (H1N1) vaccine.
    Walker WT; Faust SN
    Expert Rev Vaccines; 2010 Dec; 9(12):1385-98. PubMed ID: 21105775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and Safety of an AS03-Adjuvanted H7N9 Pandemic Influenza Vaccine in a Randomized Trial in Healthy Adults.
    Madan A; Segall N; Ferguson M; Frenette L; Kroll R; Friel D; Soni J; Li P; Innis BL; Schuind A
    J Infect Dis; 2016 Dec; 214(11):1717-1727. PubMed ID: 27609809
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased risk of anaphylaxis following administration of 2009 AS03-adjuvanted monovalent pandemic A/H1N1 (H1N1pdm09) vaccine.
    Rouleau I; De Serres G; Drolet JP; Skowronski DM; Ouakki M; Toth E; Landry M; Ménard S; Gagnon R
    Vaccine; 2013 Dec; 31(50):5989-96. PubMed ID: 24144473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion.
    Garçon N; Vaughn DW; Didierlaurent AM
    Expert Rev Vaccines; 2012 Mar; 11(3):349-66. PubMed ID: 22380826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.